Clinical and pathological heterogeneity of four common fusion subtypes in Xp11.2 translocation renal cell carcinoma

Background Xp11.2 translocation renal cell carcinoma (Xp11.2 tRCC) is a group of rare and highly heterogeneous renal cell carcinoma (RCC). The translocation involving TFE3 and different fusion partners lead to overexpression of the chimeric protein. The purpose of this study is to explore the clinicopathological features of Xp11.2 tRCC with four common fusion subtypes. Methods We screened out 40 Xp11.2 tRCC patients from January 2007 to August 2021 in our institution. The diagnosis was initially confirmed by TFE3 immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assay and their fusion partners were verified by RNA sequencing. Then the 40 cases were divided into two groups (DBHS family and non-DBHS family group) and a clinical comparison among the four common fusion subtypes was performed. Results Among the 40 cases, 11 cases with SFPQ-TFE3 gene fusion and 7 cases with NONO-TFE3 gene fusion were classified in DBHS group, the remaining cases with ASPL-TFE3 (11 cases) or PRCC-TFE3 (11 cases) gene fusion were classified in non-DBHS group. Lymph node (LN) metastasis (P=0.027) and distant metastasis (P=0.009) were more common seen in non-DBHS family group than DBHS family group and cases in DBHS family group have better progressive-free survival (PFS) (P=0.02). In addition, ASPL-TFE3 fusion was associated with worse outcome (P=0.03) while NONO-TFE3 fusion (P=0.04) predicted a better prognosis. Conclusions Different fusion partner genes may play a functional role in various morphology, molecular and biological features of Xp11.2 tRCCs. The impact of fusion partners on clinical characteristics of Xp11.2 tRCCs deserves further exploration.

[1]  Y. Zhu,et al.  Proteogenomic characterization of MiT family translocation renal cell carcinoma , 2022, Nature Communications.

[2]  Ling Yang,et al.  Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma , 2021, Nature Communications.

[3]  H. Zeng,et al.  Xp11 translocation renal cell carcinoma with morphological features mimicking multilocular cystic renal neoplasm of low malignant potential: a series of six cases with molecular analysis , 2020, Journal of Clinical Pathology.

[4]  R. Motzer,et al.  Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression , 2020, Clinical Cancer Research.

[5]  W. Xiong,et al.  NONO and tumorigenesis: More than splicing , 2020, Journal of cellular and molecular medicine.

[6]  P. Argani,et al.  MiT family translocation renal cell carcinomas: A 15th anniversary update. , 2020, Histology and histopathology.

[7]  A. Caliò,et al.  MiT Family Translocation Renal Cell Carcinoma: from the Early Descriptions to the Current Knowledge , 2019, Cancers.

[8]  K. Takayama,et al.  Splicing Factors Have an Essential Role in Prostate Cancer Progression and Androgen Receptor Signaling , 2019, Biomolecules.

[9]  S. Matteoni,et al.  SFPQ and NONO suppress RNA:DNA-hybrid-related telomere instability , 2019, Nature Communications.

[10]  R. Baxter,et al.  IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer , 2019, Cellular and Molecular Life Sciences.

[11]  T. Choueiri,et al.  Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders , 2018, Journal of Immunotherapy for Cancer.

[12]  E. V. Van Allen,et al.  The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma , 2018, Cancer Immunology Research.

[13]  Dongmei Li,et al.  PRCC-TFE3 dual-fusion FISH assay: A new method for identifying PRCC-TFE3 renal cell carcinoma in paraffin-embedded tissue , 2017, PloS one.

[14]  Erika J. Thompson,et al.  Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas , 2017, Histopathology.

[15]  C. Antonescu,et al.  RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH , 2017, The American journal of surgical pathology.

[16]  Xiao-jun Zhou,et al.  SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion. , 2017, Human pathology.

[17]  X. Teng,et al.  Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement , 2017, Modern Pathology.

[18]  Q. Rao,et al.  Xp11 Translocation Renal Cell Carcinoma and the Mesenchymal Counterparts: An Evolving Concept with Novel Insights on Clinicopathologic Features, Prognosis, Treatment, and Classification. , 2017, Critical reviews in oncogenesis.

[19]  P. Humphrey,et al.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. , 2016, European urology.

[20]  C. Antonescu,et al.  TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers , 2016, The American journal of surgical pathology.

[21]  C. Bond,et al.  The DBHS proteins SFPQ, NONO and PSPC1: a multipurpose molecular scaffold , 2016, Nucleic acids research.

[22]  N. Dimitrova,et al.  Identification of a novel PARP14‐TFE3 gene fusion from 10‐year‐old FFPE tissue by RNA‐seq , 2015, Genes, chromosomes & cancer.

[23]  Hongqian Guo,et al.  Newly Designed Break-Apart and ASPL-TFE3 Dual-Fusion FISH Assay Are Useful in Diagnosing Xp11.2 Translocation Renal Cell Carcinoma and ASPL-TFE3 Renal Cell Carcinoma , 2015, Medicine.

[24]  P. Argani.  MiT family translocation renal cell carcinoma. , 2015, Seminars in diagnostic pathology.

[25]  Soroush Rais-Bahrami,et al.  Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers , 2014, Nature Reviews Urology.

[26]  Erika J. Thompson,et al.  Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes , 2014, Clinical Cancer Research.

[27]  M. Ladanyi,et al.  Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage , 2014, Modern Pathology.

[28]  C. Pan,et al.  High chromosomal copy number alterations in Xp11 translocation renal cell carcinomas detected by array comparative genomic hybridization are associated with aggressive behavior. , 2013, The American journal of surgical pathology.

[29]  P. Tamboli,et al.  Genomic Heterogeneity of Translocation Renal Cell Carcinoma , 2013, Clinical Cancer Research.

[30]  D. Grignon,et al.  TFE3 Break-apart FISH Has a Higher Sensitivity for Xp11.2 Translocation–associated Renal Cell Carcinoma Compared With TFE3 or Cathepsin K Immunohistochemical Staining Alone: Expanding the Morphologic Spectrum , 2013, The American journal of surgical pathology.

[31]  P. Schirmacher,et al.  Molecular heterogeneity of TFE3 activation in renal cell carcinomas , 2012, Modern Pathology.

[32]  Hung-Ming Wang,et al.  Response to Sorafenib in a Patient with Metastatic Xp11 Translocation Renal Cell Carcinoma , 2010, Clinical drug investigation.

[33]  P. Argani,et al.  Translocation renal cell carcinoma , 2008, Cancer.

[34]  M. Ladanyi,et al.  Xp11 Translocation Renal Cell Carcinoma in Adults: Expanded Clinical, Pathologic, and Genetic Spectrum , 2007, The American journal of surgical pathology.

[35]  M. Ladanyi,et al.  Aberrant Nuclear Immunoreactivity for TFE3 in Neoplasms With TFE3 Gene Fusions: A Sensitive and Specific Immunohistochemical Assay , 2003, The American journal of surgical pathology.

[36]  M. Ladanyi,et al.  PRCC-TFE3 Renal Carcinomas: Morphologic, Immunohistochemical, Ultrastructural, and Molecular Analysis of an Entity Associated With the t(X;1)(p11.2;q21) , 2002, The American journal of surgical pathology.

[37]  A. V. van Kessel,et al.  Impairment of MAD2B–PRCC interaction in mitotic checkpoint defective t(X;1)-positive renal cell carcinomas , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. Ladanyi,et al.  Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. , 2001, The American journal of pathology.

[39]  Damian Smedley,et al.  Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma , 1997, Oncogene.